Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

NCT05305131 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Cancer

Interventions

DRUG: cisplatin and gemcitabine
DRUG: induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab.

Sponsor

National University Hospital, Singapore